Canaccord lowered the firm’s price target on Inari Medical to $55 from $75 and keeps a Buy rating on the shares. The firm said they reported a beat and raise as management back-end loaded revenue guidance despite the Q1/24 beat and easier Q2/24 comps, which Canaccord views as conservative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical Reports First Quarter 2024 Financial Results
- Inari Medical management to meet with BTIG
- Inari Medical to Announce First Quarter 2024 Financial Results
- Inari Medical Announces the Release of 2023 Ethos and Sustainability Report
- Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives